Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Bristol-myers squibb company save search
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
Published: 2021-05-18 (Crawled : 12:00) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -0.06%
H: 0.58%
C: 0.28%
AGEN A | $7.42 14.86% 12.94% 1.2M
|
Health Technology
|
| O: 29.45%
H: 6.64%
C: -6.87%
antibody license
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody ProgramAgenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments
Published: 2021-05-18 (Crawled : 12:15) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -0.06%
H: 0.58%
C: 0.28%
AGEN A | $7.42 14.86% 12.94% 1.2M
|
Health Technology
|
| O: 29.45%
H: 6.64%
C: -6.87%
antibody license milestone
Bristol Myers Squibb Elects Manuel Hidalgo Medina, M.D., Ph.D. to Board of Directors
Published: 2021-05-20 (Crawled : 12:00) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -0.35%
H: 2.92%
C: 2.57%
AGEN A | $7.42 14.86% 12.94% 1.2M
|
Health Technology
|
| O: -0.6%
H: 5.9%
C: 0.6%
Melanoma to be the Most Promising Indication for the PD-1/PDL-1 Inhibitor Therapies in the U.S. and EU-5 Region - Exclusive DeepTech M-A-PTM Analysis by BIS Research
Published: 2022-10-07 (Crawled : 15:20) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: 6.33%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 0.63%
H: 0.76%
C: -0.26%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.14%
H: 0.16%
C: -0.91%
RCUS 4 | $15.43 -0.45% 0.0% 520K
|
Health Technology
|
| O: -1.93%
H: 0.53%
C: -5.94%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: -0.72%
H: 0.38%
C: -1.04%
AGEN A | $7.42 14.86% 12.94% 1.2M
|
Health Technology
|
| O: -1.78%
H: 1.45%
C: -2.55%
melanoma research
Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
Published: 2021-07-28 (Crawled : 12:00) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.16%
H: 2.06%
C: 1.67%
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
|
| O: 1.2%
H: 2.36%
C: -0.88%
AGEN A | $7.42 14.86% 12.94% 1.2M
|
Health Technology
|
| O: 1.0%
H: 5.17%
C: 4.57%
financial results results
Myelofibrosis Treatment Market to Reach $1.16 Billion, Globally, by 2031 at 4.0% CAGR: Allied Market Research
Published: 2023-02-06 (Crawled : 12:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: 2.88%
H: 1.17%
C: -2.24%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 1.64%
H: 0.24%
C: -0.17%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.0%
H: 0.98%
C: 0.11%
AMRX | $6.05 12.04% 11.04% 2.7M
|
Health Technology
|
| O: 0.0%
H: 6.58%
C: 4.53%
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: 0.37%
H: 0.4%
C: -0.49%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 0.0%
H: 1.47%
C: 0.9%
GLTO | $0.671 -4.23% -7.77% 76K
|
Health Technology
|
| O: -1.11%
H: 3.36%
C: 1.12%
treatment research market
Gritstone Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of GRANITE and Trial in Progress Poster at ASCO
Published: 2022-05-31 (Crawled : 17:00) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -1.39%
H: 1.2%
C: 0.49%
GRTS | $0.8129 10.06% 9.92% 1.8M
|
Health Technology
|
| O: 7.03%
H: 18.69%
C: 2.02%
trial asco results cancer phase 1
Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial
Published: 2021-09-17 (Crawled : 12:00) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -1.14%
H: 0.0%
C: 0.0%
GRTS | $0.8129 10.06% 9.92% 1.8M
|
Health Technology
|
| O: 3.4%
H: 0.0%
C: 0.0%
phase 2 immunotherapy therapy trial solid tumors
Gritstone Announces Positive Clinical Data with GRANITE (Individualized Neoantigen Immunotherapy Program) during ESMO 2021 and Launch of Randomized Clinical Trial Program in Colorectal Cancer with Registrational Intent
Published: 2021-09-17 (Crawled : 12:00) - globenewswire.com
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -1.14%
H: 0.0%
C: 0.0%
GRTS | $0.8129 10.06% 9.92% 1.8M
|
Health Technology
|
| O: 3.4%
H: 0.0%
C: 0.0%
immunotherapy positive therapy cancer colorectal cancer trial program
Gritstone Presentations at AACR Further Support Expertise in Neoantigen Vaccine Design and Delivery
Published: 2022-04-12 (Crawled : 21:00) - globenewswire.com
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.24%
H: 0.53%
C: 0.18%
GRTS | $0.8129 10.06% 9.92% 1.8M
|
Health Technology
|
| O: 1.63%
H: 2.0%
C: 0.8%
vaccine designation
Purple Biotech Announces the Initiation of Phase 2 Study for CM24 in 2L PDAC Patients
Published: 2022-05-18 (Crawled : 12:20) - globenewswire.com
PPBT | $0.5127 4.63% 9.09% 270K
|
Manufacturing
|
| O: -0.67%
H: 8.08%
C: 2.69%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
cm24 biotech purple phase 2
Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting
Published: 2022-04-11 (Crawled : 12:00) - globenewswire.com
PPBT | $0.5127 4.63% 9.09% 270K
|
Manufacturing
|
| O: -4.28%
H: 0.0%
C: -26.84%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -0.09%
H: 0.55%
C: -1.54%
cm24 research biotech positive results cancer phase 2b
Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Published: 2022-08-10 (Crawled : 23:00) - biospace.com/
GNMSF | News | $290.34 0.23% 3.83% 1.2K
|
Health Technology
|
| O: -0.39%
H: 5.07%
C: -0.05%
BOLT | $1.2002 8.13% 6.72% 150K
|
|
| O: 3.07%
H: 8.51%
C: 7.23%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.32%
H: 0.16%
C: -0.45%
GMAB | News | $28.47 -0.32% -0.32% 430K
|
Health Technology
|
| O: 2.33%
H: 0.64%
C: -0.72%
update results
Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting
Published: 2022-11-07 (Crawled : 18:00) - biospace.com/
BOLT | $1.2002 8.13% 6.72% 150K
|
|
| O: 0.75%
H: 1.87%
C: -1.48%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -0.09%
H: 1.23%
C: 0.61%
bdc-3042 preclinical meeting
Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo® for Treatment of HER2-Expressing Solid Tumors
Published: 2021-09-08 (Crawled : 12:00) - globenewswire.com
BOLT | $1.2002 8.13% 6.72% 150K
|
|
| O: 0.76%
H: 0.0%
C: -7.09%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -0.89%
H: 0.82%
C: 0.48%
treatment solid tumors collaboration iot her2+ her2- her2
Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021
Published: 2021-12-02 (Crawled : 11:00) - globenewswire.com
BOLT | $1.2002 8.13% 6.72% 150K
|
|
| O: 3.22%
H: 8.6%
C: 6.35%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 2.17%
H: 0.0%
C: 0.0%
trial therapeutics phase 1 iot
Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021
Published: 2021-12-06 (Crawled : 12:00) - biospace.com/
BOLT | $1.2002 8.13% 6.72% 150K
|
|
| O: -22.84%
H: 0.0%
C: 0.0%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: 0.0%
therapeutics phase 1 iot
Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors
Published: 2022-01-06 (Crawled : 14:30) - biospace.com/
BOLT | $1.2002 8.13% 6.72% 150K
|
|
| O: -4.05%
H: 2.98%
C: -7.2%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -1.17%
H: 0.11%
C: -0.39%
bdc-1001 opdivo treatment solid tumors ongoing trial therapeutics 100 phase 1 iot her2- her2 nivolumab
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Published: 2023-03-29 (Crawled : 22:00) - globenewswire.com
FNCTF | News | $11.16 1.13% -20.84% 0
|
Communications
|
| O: 1.48%
H: 0.0%
C: 0.0%
GNMSF | News | $290.34 0.23% 3.83% 1.2K
|
Health Technology
|
| O: 0.0%
H: 1.69%
C: 1.42%
BOLT | $1.2002 8.13% 6.72% 150K
|
|
| O: 5.43%
H: 0.74%
C: -1.47%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.29%
H: 0.22%
C: -0.26%
GMAB | News | $28.47 -0.32% -0.32% 430K
|
Health Technology
|
| O: 0.37%
H: 0.05%
C: -0.4%
business year update financial results
Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings
Published: 2021-09-21 (Crawled : 20:00) - globenewswire.com
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.28%
H: 0.26%
C: -0.58%
ABT | News | $106.89 -0.65% -0.09% 4.2M
|
Health Technology
|
| O: 0.3%
H: 0.19%
C: -0.68%
SRPT | $124.25 6.09% 5.75% 1.5M
|
Health Technology
|
| O: -0.25%
H: 1.24%
C: 0.08%
ABEO | News | $3.17 -7.04% -7.74% 2.1M
|
Health Technology
|
| O: -1.65%
H: 4.2%
C: 0.0%
license
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.